Market by Product, Application, Source Type, and Country | Forecast 2021-2028
As stated in Triton’s research report, the Asia-Pacific biosurgery market is projected to grow at 7.56% of CAGR during the period 2021-2028.
Report scope can be customized per your requirements. Request For Customization
The
countries considered in this market include:
• India
• China
• Japan
• Australia & New Zealand
• South Korea
• ASEAN countries
• Rest of Asia-Pacific
The
studied market’s growth in the region is supported by various factors, such as
the rising occurrence of chronic diseases, the increase in surgical procedures,
and the development of new products. Furthermore, due to the growth in
lifestyle diseases and the surge in geriatric populations, the demand for
biosurgery products has increased across the major nations, including China and
Japan. Hence, these factors are largely supporting the growth of the biosurgery
market over the forecast period.
China,
for instance, has a well-developed healthcare industry across the region. The
rising number of patients suffering from chronic diseases, along with the
growing number of surgical procedures, are anticipated to supplement the
studied market’s progress. As per estimates, in recent years, the number of
cancer patients has surged across the country, resulting in multiple patients
opting for surgeries to remove the tumor. Other than this, the surge in
cardiovascular diseases has augmented the demand for biosurgery products,
thereby widening the scope and growth of the Chinese biosurgery market over the
estimated period.
Likewise,
the number of aging populations is anticipated to proliferate across Japan by
2050. This rise will increase the prevalence of chronic conditions among
geriatric people, enhancing the demand for biosurgery products. Thus, as
mentioned above, these factors are likely to boost the biosurgery market’s
growth.
CSL
Limited is involved in offering products used to treat and prevent rare medical
conditions. It majorly operates through its human health segment. Besides, the
company’s products are used for various applications, including hematology,
cardiovascular, metabolic, transplant, and respiratory. Moreover, it offers a
wide range of products to the Australian government. CSL has business
operations across various countries, with headquarters located in Melbourne,
Australia.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. ASIA-PACIFIC
BIOSURGERY MARKET - SUMMARY
2. INDUSTRY
OUTLOOK
2.1. IMPACT
OF COVID-19 ON BIOSURGERY MARKET
2.2. TRENDS
IN BIOSURGERY TECHNOLOGY
2.3. KEY
INSIGHTS
2.4. PORTER’S
FIVE FORCES MODEL
2.4.1. THREAT
OF NEW ENTRANTS
2.4.2. THREAT
OF SUBSTITUTE PRODUCTS
2.4.3. BARGAINING
POWER OF BUYERS
2.4.4. BARGAINING
POWER OF SUPPLIERS
2.4.5. COMPETITIVE
RIVALRY
2.5. MARKET
ATTRACTIVENESS INDEX
2.6. VENDOR
SCORECARD
2.7. KEY
BUYING OUTLOOK
2.8. KEY
MARKET STRATEGIES
2.8.1. CONTRACTS
AND PARTNERSHIPS
2.8.2. BUSINESS
EXPANSIONS, ANNOUNCEMENTS, & DIVESTITURES
2.8.3. ACQUISITIONS
& MERGERS
2.8.4. NEW
PRODUCT LAUNCHES & DEVELOPMENTS
2.9. MARKET
DRIVERS
2.9.1. GROWING
AGING POPULATION
2.9.2. TECHNOLOGICAL
ADVANCEMENTS AND INNOVATIONS IN HEALTHCARE FACILITIES
2.9.3. SURGE
IN SURGICAL TREATMENTS FOR MUSCULOSKELETAL DISORDERS
2.9.4. PREVALENCE
OF SPINAL FUSION AND JOINT RECONSTRUCTION
2.9.5. STRONG
FOCUS ON RESEARCH AND DEVELOPMENT
2.10. MARKET
CHALLENGES
2.10.1. HIGH
COST OF SURGERIES
2.10.2. COMPLICATIONS
RELATED TO IMMUNE RESPONSE
2.10.3. USAGE
OF MINIMALLY INVASIVE SURGERIES
2.11. MARKET
OPPORTUNITIES
2.11.1. RESEARCH
AND INVESTMENTS IN BIOENGINEERING
2.11.2. DEVELOPMENT
OF POLICIES FOR REIMBURSEMENT AND COMPENSATION
3. ASIA-PACIFIC
BIOSURGERY MARKET - BY PRODUCT
3.1. HEMOSTATIC
AGENTS
3.2. BONE-GRAFT
SUBSTITUTES
3.2.1. SYNTHETIC
GRAFT EXTENDERS
3.2.2. DEMINERALIZED
BONE MATRIX
3.2.3. BONE
MORPHOGENETIC PROTEINS
3.2.4. CELL-BASED
MATRICES
3.3. SURGICAL
SEALING AGENTS
3.3.1. NATURAL
3.3.2. SYNTHETIC
3.4. SOFT-TISSUE
MANAGEMENT
3.4.1. SYNTHETIC
MESH/PATCH
3.4.2. NATURAL
MESH/PATCH
3.5. ANTI-ADHESIVE
AGENTS
3.6. STAPLE
LINE REINFORCEMENT
4. ASIA-PACIFIC
BIOSURGERY MARKET - BY APPLICATION
4.1. ORTHOPEDIC
SURGERY
4.2. CARDIO
AND THORACIC SURGERY
4.3. NEURO
AND SPINE SURGERY
4.4. GENERAL
SURGERY
4.5. OTHER
APPLICATIONS
5. ASIA-PACIFIC
BIOSURGERY MARKET – BY SOURCE TYPE
5.1. NATURAL
5.2. SYNTHETIC
6. ASIA-PACIFIC
BIOSURGERY MARKET – COUNTRY OUTLOOK
6.1. COUNTRY
ANALYSIS
6.1.1. CHINA
6.1.2. JAPAN
6.1.3. INDIA
6.1.4. AUSTRALIA
& NEW ZEALAND
6.1.5. SOUTH
KOREA
6.1.6. ASEAN
COUNTRIES
6.1.7. REST
OF ASIA-PACIFIC
7. COMPETITIVE
LANDSCAPE
7.1. BAXTER
INTERNATIONAL INC
7.2. BECTON,
DICKINSON AND COMPANY
7.3. B
BRAUN MELSUNGEN AG
7.4. CSL
LIMITED
7.5. ETHICON
INC (JOHNSON & JOHNSON)
7.6. INTEGRA
LIFESCIENCES HOLDINGS CORPORATION
7.7. MEDTRONIC
PLC
7.8. RTI
SURGICAL
7.9. SANOFI
7.10. SMITH
& NEPHEW PLC
7.11. STRYKER
CORPORATION
7.12. WRIGHT
MEDICAL GROUP NV
7.13. ZIMMER
BIOMET HOLDINGS INC
8. RESEARCH
METHODOLOGY & SCOPE
8.1. RESEARCH
SCOPE & DELIVERABLES
8.1.1. OBJECTIVES
OF STUDY
8.1.2. SCOPE
OF STUDY
8.2. SOURCES
OF DATA
8.2.1. PRIMARY
DATA SOURCES
8.2.2. SECONDARY
DATA SOURCES
8.3. RESEARCH
METHODOLOGY
8.3.1. EVALUATION
OF PROPOSED MARKET
8.3.2. IDENTIFICATION
OF DATA SOURCES
8.3.3. ASSESSMENT
OF MARKET DETERMINANTS
8.3.4. DATA
COLLECTION
8.3.5. DATA
VALIDATION & ANALYSIS
TABLE 1: ASIA-PACIFIC
BIOSURGERY MARKET, COUNTRY OUTLOOK, 2021-2028 (IN $ MILLION)
TABLE 2: VENDOR SCORECARD
TABLE 3: CONTRACTS AND
PARTNERSHIPS
TABLE 4: BUSINESS EXPANSIONS,
ANNOUNCEMENTS, & DIVESTITURES
TABLE 5: ACQUISITIONS &
MERGERS
TABLE 6: NEW PRODUCT LAUNCHES
& DEVELOPMENTS
TABLE 7: ASIA-PACIFIC
BIOSURGERY MARKET, BY PRODUCT, 2021-2028 (IN $ MILLION)
TABLE 8: ASIA-PACIFIC
BONE-GRAFT SUBSTITUTES MARKET, BY TYPE, 2021-2028 (IN $ MILLION)
TABLE 9: ASIA-PACIFIC SURGICAL
SEALING AGENTS MARKET, BY TYPE, 2021-2028 (IN $ MILLION)
TABLE 10: ASIA-PACIFIC
SOFT-TISSUE MANAGEMENT MARKET, BY TYPE, 2021-2028 (IN $ MILLION)
TABLE 11: ASIA-PACIFIC
BIOSURGERY MARKET, BY APPLICATION, 2021-2028 (IN $ MILLION)
TABLE 12: ASIA-PACIFIC
BIOSURGERY MARKET, BY SOURCE TYPE, 2021-2028 (IN $ MILLION)
TABLE 13: ASIA-PACIFIC
BIOSURGERY MARKET, COUNTRY OUTLOOK, 2021-2028 (IN $ MILLION)
FIGURE 1: ASIA-PACIFIC
BIOSURGERY MARKET 2021-2028 (IN $ MILLION)
FIGURE 2: ASIA-PACIFIC
BIOSURGERY MARKET, BY PRODUCT, 2020 & 2028 (IN %)
FIGURE 3: ASIA-PACIFIC BIOSURGERY
MARKET, BY HEMOSTATIC AGENTS, 2021-2028 (IN $ MILLION)
FIGURE 4: ASIA-PACIFIC
BIOSURGERY MARKET, BY BONE-GRAFT SUBSTITUTES, 2021-2028 (IN $ MILLION)
FIGURE 5: ASIA-PACIFIC
BONE-GRAFT SUBSTITUTES MARKET, BY SYNTHETIC GRAFT EXTENDERS, 2021-2028 (IN $
MILLION)
FIGURE 6: ASIA-PACIFIC
BONE-GRAFT SUBSTITUTES MARKET, BY DEMINERALIZED BONE MATRIX, 2021-2028 (IN $
MILLION)
FIGURE 7: ASIA-PACIFIC
BONE-GRAFT SUBSTITUTES MARKET, BY BONE MORPHOGENETIC PROTEINS, 2021-2028 (IN $
MILLION)
FIGURE 8: ASIA-PACIFIC BONE-GRAFT
SUBSTITUTES MARKET, BY CELL-BASED MATRICES, 2021-2028 (IN $ MILLION)
FIGURE 9: ASIA-PACIFIC
BIOSURGERY MARKET, BY SURGICAL SEALING AGENTS, 2021-2028 (IN $ MILLION)
FIGURE 10: ASIA-PACIFIC SURGICAL
SEALING AGENTS MARKET, BY NATURAL, 2021-2028 (IN $ MILLION)
FIGURE 11: ASIA-PACIFIC SURGICAL
SEALING AGENTS MARKET, BY SYNTHETIC, 2021-2028 (IN $ MILLION)
FIGURE 12: ASIA-PACIFIC BIOSURGERY
MARKET, BY SOFT-TISSUE MANAGEMENT, 2021-2028 (IN $ MILLION)
FIGURE 13: ASIA-PACIFIC SOFT-TISSUE
MANAGEMENT MARKET, BY SYNTHETIC MESH/PATCH, 2021-2028 (IN $ MILLION)
FIGURE 14: ASIA-PACIFIC SOFT-TISSUE
MANAGEMENT MARKET, BY NATURAL MESH/PATCH, 2021-2028 (IN $ MILLION)
FIGURE 15: ASIA-PACIFIC BIOSURGERY
MARKET, BY ANTI-ADHESIVE AGENTS, 2021-2028 (IN $ MILLION)
FIGURE 16: ASIA-PACIFIC BIOSURGERY
MARKET, BY STAPLE LINE REINFORCEMENT, 2021-2028 (IN $ MILLION)
FIGURE 17: ASIA-PACIFIC BIOSURGERY
MARKET, BY APPLICATION, 2020 & 2028 (IN %)
FIGURE 18: ASIA-PACIFIC BIOSURGERY
MARKET, BY ORTHOPEDIC SURGERY, 2021-2028 (IN $ MILLION)
FIGURE 19: ASIA-PACIFIC BIOSURGERY
MARKET, BY CARDIO AND THORACIC SURGERY, 2021-2028 (IN $ MILLION)
FIGURE 20: ASIA-PACIFIC BIOSURGERY
MARKET, BY NEURO AND SPINE SURGERY, 2021-2028 (IN $ MILLION)
FIGURE 21: ASIA-PACIFIC BIOSURGERY
MARKET, BY GENERAL SURGERY, 2021-2028 (IN $ MILLION)
FIGURE 22: ASIA-PACIFIC BIOSURGERY
MARKET, BY OTHER APPLICATIONS, 2021-2028 (IN $ MILLION)
FIGURE 23: ASIA-PACIFIC BIOSURGERY
MARKET, BY SOURCE TYPE, 2020 & 2028 (IN %)
FIGURE 24: ASIA-PACIFIC BIOSURGERY
MARKET, BY NATURAL, 2021-2028 (IN $ MILLION)
FIGURE 25: ASIA-PACIFIC BIOSURGERY
MARKET, BY SYNTHETIC, 2021-2028 (IN $ MILLION)
FIGURE 26: CHINA BIOSURGERY MARKET
2021-2028 (IN $ MILLION)
FIGURE 27: JAPAN BIOSURGERY MARKET
2021-2028 (IN $ MILLION)
FIGURE 28: INDIA BIOSURGERY MARKET
2021-2028 (IN $ MILLION)
FIGURE 29: AUSTRALIA & NEW
ZEALAND BIOSURGERY MARKET 2021-2028 (IN $ MILLION)
FIGURE 30: SOUTH KOREA BIOSURGERY
MARKET 2021-2028 (IN $ MILLION)
FIGURE 31: ASEAN COUNTRIES
BIOSURGERY MARKET 2021-2028 (IN $ MILLION)
FIGURE 32: REST OF ASIA-PACIFIC
BIOSURGERY MARKET 2021-2028 (IN $ MILLION)